FY2030 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Invivyd in a report released on Friday, January 23rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.16 per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share.

A number of other research analysts have also recently commented on IVVD. D Boral Capital cut Invivyd from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. BTIG Research restated a “buy” rating on shares of Invivyd in a research report on Wednesday. Cantor Fitzgerald initiated coverage on shares of Invivyd in a report on Monday, October 6th. They set an “overweight” rating and a $10.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $8.00.

Invivyd Trading Down 4.5%

NASDAQ IVVD opened at $2.11 on Monday. The company has a market cap of $491.88 million, a price-to-earnings ratio of -4.49 and a beta of 0.61. The company has a 50 day moving average of $2.43 and a 200-day moving average of $1.64. Invivyd has a 1-year low of $0.35 and a 1-year high of $3.07.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.

Insider Activity

In other news, Director Kevin F. Mclaughlin acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average price of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director directly owned 50,000 shares in the company, valued at $125,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 25.40% of the company’s stock.

Hedge Funds Weigh In On Invivyd

A number of institutional investors and hedge funds have recently bought and sold shares of IVVD. Catalyst Funds Management Pty Ltd acquired a new position in Invivyd in the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC grew its stake in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Jane Street Group LLC acquired a new stake in Invivyd in the second quarter valued at $147,000. Squarepoint Ops LLC increased its holdings in Invivyd by 188.9% in the third quarter. Squarepoint Ops LLC now owns 107,831 shares of the company’s stock valued at $119,000 after purchasing an additional 70,508 shares during the period. Finally, Bridgeway Capital Management LLC bought a new position in Invivyd during the 3rd quarter worth $109,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.